Aledort Louis M
Department of Medicine, Mount Sinai School of Medicine, New York, NY 10029-6574, USA.
Pathophysiol Haemost Thromb. 2003;33(1):2-3. doi: 10.1159/000071635.
Intervention for clotting and bleeding disorders is costly, and clear-cut regimens undefined. The margin of safety between hemostasis and thrombosis is narrow and unpredictable. The use of a laboratory test to help define therapeutic regimens, dissect effects of these treatments, and to differentiate them are clearly needed. The current state of the art of thrombin generation is ready to do this.
针对凝血和出血性疾病的干预措施成本高昂，且尚无明确的治疗方案。止血和血栓形成之间的安全界限狭窄且难以预测。显然需要借助实验室检测来帮助确定治疗方案、剖析这些治疗的效果并加以区分。目前凝血酶生成的技术水平已能够做到这一点。
